Upadacitinib is a selective JAK1 inhibitor used in the treatment of autoimmune disorders including RA, atopic dermatitis, psoriatic arthritis, and ulcerative colitis.64 In a phase II, double-blind trial of 341 SLE patients receiving elsubrutinib/upadacitinib combination therapy, upadacitinib monotherapy or placebo both therapeutic regimens significantly improved disease activity and risk of relapse.65 Both primary and key secondary endpoints were achieved whereas anti-double stranded DNA antibodies also significantly decreased in response to treatment. Here, JAK1 is linked to systemic lupus erythematosus.